ZEISS to Unveil AI-Powered Retinal Surgery and Diagnostic Innovations at EURETINA 2024

ZEISS to Unveil AI-Powered Retinal Surgery and Diagnostic Innovations at EURETINA 2024

(IN BRIEF) ZEISS Medical Technology will introduce new digital and AI-driven innovations at the EURETINA 2024 conference. Key highlights include the ZEISS ARTEVO 850 3D digital visualization system and the EVA NEXUS surgical system, which enhance precision and safety in retinal surgery. Additionally, ZEISS will showcase the CIRRUS PathFinder, an AI tool for streamlining the review of OCT data, and the ZEISS Surgery Optimizer, an AI-powered platform for managing surgical videos. These advancements aim to improve the efficiency of retinal surgeries and diagnostics, providing better outcomes for patients.

(PRESS RELEASE) JENA, 13-Sep-2024 — /EuropaWire/ — At the upcoming EURETINA 2024 conference, ZEISS Medical Technology will unveil cutting-edge innovations aimed at advancing vitreoretinal surgery and retinal care. Among the highlights is the ZEISS ARTEVO 850, a 3D digital visualization system that provides surgeons with improved depth of field and high-quality imaging during eye surgery. ZEISS will also demonstrate its single-use lenses for the RESIGHT system, offering enhanced patient safety, as well as the EVA NEXUS surgical system from DORC, which now complements ZEISS’s portfolio.

In addition to surgical advancements, ZEISS will showcase its latest AI tools designed to streamline retinal diagnostics, such as the CIRRUS PathFinder, which helps doctors efficiently analyze large volumes of OCT data. This system flags scans that may require further review, assisting in early disease detection and treatment optimization.

ZEISS will also debut an AI-powered application for simplifying surgical video management, allowing ophthalmologists to review and analyze surgeries using the Apple Vision Pro, enhancing the post-surgery analysis experience.

These innovations form part of ZEISS’s comprehensive approach to integrating digital technology into retinal care, reinforcing its position as a leader in ophthalmic solutions.

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

• 1Compared to ARTEVO 800, data on file.
• 2PathFinder works on all current CIRRUS devices: 500, 5000, 6000, pending local regulatory clearances.
• 3ZEISS Surgery Optimizer is a non-medical device and not intended for diagnosing, treatment, or prophylactic activities.
• 4Only works on iPhone or iPad. iPhone and iPad are trademarks of Apple Inc iOS is a trademark of Cisco technology, Inc.
• 5The concept on Apple Vision Pro only allows the review of pre-selected clinical cases.

Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals’ content.

The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support.

Media Contacts:

Investors:
Sebastian Frericks
Head of Group Finance and Investor Relations
Carl Zeiss Meditec AG
Tel:+49 3641 220 116
investors.med@zeiss.com

Press:
Frank E. Smith
Head of Global Communications Ophthalmic Devices
Carl Zeiss Meditec Inc.
Tel:+49 3641 220 331
press.med@zeiss.com

SOURCE: ZEISS